… the Phase 3 trial protocol to the FDA in the … recent approvals of injectable drugs for this indication, there … Roxadustat Roxadustat, an oral medication, is the first in … for the treatment of metastatic castration-resistant prostate cancer. This program …

… to add further information after Pharmaceutical Technology’s request, saying … for Bayer’s newly launched drugs. Prostate cancer therapy Nubeqa (darolutamide) grew … recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation …

… were deemed possibly related to treatment occurred in 6 patients in … the EXTEND trial remains ongoing to evaluate the effects of treatment on … for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol …

Please enable Javascript 1:56-4:02 - Importance of trial design in therapy selection 4:02-8:09 - Benefits of cooperative trials and comparison of trial end points 8:09-12:10 - Applicability of trial inclusion criteria in daily practice 12:10-13:17 - Moving …

Panelists discuss how NCCN guidelines provide a framework for selecting appropriate androgen deprivation therapy (ADT) regimens across different disease states, with combination therapies now being standard of care rather than ADT monotherapy in most cases …

… drugs do come with a significant caveat, however: The Food and Drug … thyroid cancer to avoid the medications. What exactly is the … meeting in September. The FDA advisory on GLP-1s specifically … growing, kind of like small prostate cancer. Ninety-five percent of …

… patients with prostate cancer.1 The FDA has set a Prescription Drug User Fee … positioned for continued leadership in prostate cancer imaging.” Findings from the phase … on our commitment to advance prostate cancer imaging through sustainable innovation,” Paul …

… driver successfully treated for prostate cancer decided to take two … been diagnosed with prostate cancer and receiving treatment since May 2024. … to it helping other prostate cancer patients like himself. Ronnie … the link. We also treat our community members to …

… pharmacy counter. The average cost of developing a new drug … illness and respond to treatment in clinical practice. Yet … begin. For example, in prostate cancer research, traditional claims data … matter. They guide better trial design, better stratification, and …

… that the Food and Drug Administration (FDA) has accepted a … of allergy to other drugs and foods. Reactions may … North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company. … recurrent prostate cancer after primary local therapy. J Nucl Med. 2020 …